JAMA Neurology Journal

Overview
Identity
View All

publication venue for

Computed Tomography Perfusion and Angiography for Death by Neurologic Criteria.. 82. 2025
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021.. 82. 2025
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.. 82:450-460. 2025
Immortal Time Bias and Nonlinear Stroke Recurrence Risk.. 82:527. 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.. 82:477-485. 2025
Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke. 80:824-824. 2023
Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes. 80:251-251. 2023
Association of Genetic Variant Linked to Hemochromatosis With Brain Magnetic Resonance Imaging Measures of Iron and Movement Disorders. 79:919-919. 2022
Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source. 79:450-450. 2022
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin. 78:1454-1454. 2021
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis. 78:1333-1333. 2021
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. 78:11-11. 2021
A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage. 77:1390-1390. 2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source. 77:1233-1233. 2020
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. 77:43-43. 2020
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment—Reply. 77:134-134. 2020
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. 76:764-764. 2019
Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity. 76:480-480. 2019
Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. 76:301-301. 2019
Cerebral Microbleeds and the Effect of Intensive Blood Pressure Reduction on Hematoma Expansion and Functional Outcomes. 75:850-850. 2018
Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease. 73:431-431. 2016
Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related Inflammation. 73:197-197. 2016
Rarity of the Alzheimer Disease–ProtectiveAPPA673T Variant in the United States. 72:209-209. 2015
Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. 71:1394-1394. 2014
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. 71:141-141. 2014
Direct-Acting Oral Anticoagulants. 70:1483-1484. 2013
Sex, Stroke, and Atrial Fibrillation. 69:1641-1641. 2012
Statins and Intracerebral Hemorrhage. 69:39-39. 2012
Postvaccination Miller Fisher Syndrome. 68:1327-1327. 2011
Possible Influence of Stroke Etiology on Hemorrhagic Transformation Following Thrombolysis in Warfarin-Treated Patients. 67:1413-1413. 2010
Measuring Demyelination and Remyelination in Acute Multiple Sclerosis Lesion Voxels. 66:375-381. 2009
Strategic Subcortical Hyperintensities in Cholinergic Pathways and Executive Function Decline in Treated Alzheimer Patients. 64:266-266. 2007
Presence of Alanine-to-Valine Substitutions in Myofibrillogenesis Regulator 1 in Paroxysmal Nonkinesigenic Dyskinesia. 62:597-597. 2005
Dementia With Lewy Bodies and the Neurobehavioral Decline of Mervyn Peake. 60:889-889. 2003
Plasticity, Hippocampal Place Cells, and Cognitive Maps. 58:874-874. 2001
Anticoagulation Therapy in Pediatric Patients With Sinovenous Thrombosis. 55:1533-1533. 1998
Prothrombotic Disorders in Infants and Children With Cerebral Thromboembolism. 55:1539-1539. 1998
Clinical Decision Making in Severe Brain Injury. 49:349-350. 1992
Duchenne Muscular Dystrophy Manifesting Carriers. 47:951-951. 1990
Cerebrospinal Fluid Somatostatin and Neuropeptide Y. 45:269-269. 1988
Therapeutic Range for the Control of Oral Anticoagulant Therapy. 43:1162-1164. 1986
Amyotrophic Lateral Sclerosis. 30:242-242. 1974
Multiple Muscle Analysis of Motor Units in Muscular Dystrophy. 30:249-251. 1974